Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease

Journal of Nephrology

Volumn 12, Issue 4, 1999, Pages 248-255

  Blacher, Jacques ^a   Demuth, Karins ^a   Guerin, Alain P ^b   Vadez, Chantal ^a   Moatti, Nicole ^c   Safar, Michel E ^a   London, Gérard M ^b  

^a HÔPITAL BROUSSAIS   (France)

^b Hopital Manhes   (France)

^c Hôpital Manhes ^*

Author keywords

Cardiac mass; Cardiovascular risk; Hemodialysis; Homocysteine; Uremia

Indexed keywords

ALBUMIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; PHOSPHATE; TRIACYLGLYCEROL; UREA;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; SEX; SYSTOLIC BLOOD PRESSURE;

BLOOD PRESSURE; FEMALE; FOLIC ACID; HEMATOCRIT; HOMOCYSTEINE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; RENAL DIALYSIS; RISK FACTORS; VITAMIN B 12;

EID: 0032853563     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1074-57.
2. Malinow MR, Ducimetiere P, Luc G, Evans AE, Arveiler D, Cambien F, Upson BM. Plasma homocysteine levels and graded risk for myocardial infarction: finding in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996; 126: 27-34.
3. Blacher J, Montalescot G, Ankri A, Chadefaux-Vekemans B, Benzidia R, Grosgogeat Y, Thomas D. Hyperhomocystèinèmie chez des patients coronariens. A propos de une etude portant sur 102 sujets. Arch Mal Coeur 1996; 1241-6.
4. Alfthan G, Aro A, Gey KF. Plasma homocysteine and cardiovascular disease mortality. Lancet 1997; 349: 97.
5. Chauveau P, Chadefaux B, Coudé M, Aupetit J, Hannedouche T, Kamoun P, Jungers P. Hyperhomocysteinemia, a risk factor for atherosclerosis in chronic uremic patients. Kidney Int 1993; 43 (suppl 41): S72-7.
6. Smolin LA, Laidlaw SA, Kopple JD. Altered plasma free and protein-bound sulfur amino acids in patients undergoing maintenance hemodialysis. Am J Clin Nutr 1987; 45: 737-43.
7. Bostom AG, Shemin D, Verhoef P, Nadeau M, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Total plasma homocysteine levels and overall and cardiovascular disease-specific mortality in maintenance dialysis patients. (Abstract) Circulation 1996; 94 (suppl): 1-457.
8. Raine AEG, Margreiter R, Brunner FP, Ehrich JHH, Geerlings W, Landais P, Loirat C, Mallick NP, Selwood NH, Tufveson G, Valderrabano F. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7 (suppl.2): 1-48.
9. London GM, Marchais SJ, Guerin AP, Fabiani F, Metivier F. Cardiovascular function in hemodialysis patients. In: Grünfeld JP, Bach JF, Funck Brentano JL, Maxwell MH, eds. Advances in Nephrology. Vol 20. St. Louis: Mosby Year Book Publishers, 1991; 249-73.
10. Koren MJ, Devereux RB, Casale PN, Savage D, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345-52.
11. Silberberg JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy on survival in end stage renal disease. Kidney Int 1989; 36: 286-90.
12. Fortin LJ, Genest J. Measurement of homocyst(c)ine in the prediction of atherosclerosis. Clin Biochem 1995; 28: 155-62.
13. Kuemmerle SC, Boltinghouse GL, Delby SM, Lane TL, Simondsen RP. Automated assay of vitamin B 12 by the Abbott IMX analyzer. Clin Chem 1992; 38: 2073-77.
14. Wilson DH, Herrmann R, Hsu S, et al. Ion capture assay for folate with the Abbott IMX analyzer. Clin Chem 1995; 41: 1780-1.
15. Sahn DJ, De Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiographic measurements. Circulation 1978; 58: 1072-83.
16. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: Anatomic validation of the method. Circulation 1977; 55: 613-8.
17. Devereux RB, Liebson PR, Horan MJ. Recommendations concerning use of echocardiography in hypertension and in general population research. Hypertension 1987; 9 (suppl 2): S97-104.
18. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease: Comparative effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90: 2786-96.
19. Hintze JL. Number cruncher statistical system 1995. User manual. Ireland: Statistical Solutions Limited, November 1995.
20. British Standards Institution. Precision of test methods. 1: guide for the determination of reproducibility for a standard test method. London, England: British Standards Institution; 1979. BS 5497, part 1.
21. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19: 251-3.
22. Ma KW, Greene EL, Raji L. Cardiovascular risk factors in chronic renal failure and hemodialysis populations. Am J Kidney Dis 1992; 19: 505-13.
23. Hultberg B, Andersson A, Sterner G. Plasma homocysteine in renal failure. Clin Nephrol 1993; 40: 2304.
24. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR. Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 1988; 37: 697-701.
25. Tizianello A, De Ferrari G, Garibotto G. Gurreri G, Robaudo C. Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. J Clin Invest 1980; 65: 1162.
26. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PWF, Selhub J. Hypermocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995; 114: 93-103.
27. Ueland PM, Refsum H, Brattstrom LA. Plasma homocysteine and cardiovascular disease. In: Francis RBJ ed. Atherosclerotic Cardiovascular Disease. Hemostasis and Endothelial Function. New York: Marcel Dekker 1992; 183.
28. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J, Rosenberg IH. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996; 123: 193-202.
29. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PWF, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 1995; 332: 286-91.
30. Malinow MR, Nieto FJ, Szklo M, Chambless LE, Bond G. Carotid artery intimal-medial wall thickening and plasma homocysteine in asymptomatic adults. Circulation 1993; 87: 1107-13.
31. Heinecke JW, Rosen H, Suzuki LA, Chait A. The role of sulfurcontaining amino acids in superoxide production and modification of low density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 1098-103.
32. Blann AD. Endothelial cell damage and homocysteine. Atherosclerosis 1992; 94: 89-91.
33. Di Minno G, Davi G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, Catalano I, Strisciuolio P, Andria G, Patrono P. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest 1993; 92: 1400-6.
34. Tsai JC, Perrella MA, Yoshizumi M. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-73.
35. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-14.
36. O'Rourke MF. Vascular Impedance: The relationship between pressure and flow. In Arterial Function in Health and Disease. Edinburgh: Churchill Livingstone Publisher, 1982, 94-132, 185-243.
37. London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, Metivier F. Cardiac and arterial interactions in end-stage renal disease. Kidney Int 1996; 50: 600-8.
38. Marchais SJ, Guerin AP, Pannier BM, Levy BI, Safar ME, London GM. Wave reflections and cardiac hypertrophy in chronic uremia. Influence of body size. Hypertension 1993; 22: 876-83.
39. Ubbink JB, Vermaak WJH, Bennett JM, Becker PJ, Van Staden DA, Bissbort S. The prevalence of homocysteinemia and hypercholesterolemia in angiographically defined coronary heart disease. Klin Wochenschr 1991; 69: 527-34.
40. Herzlich BC, Lichstein E, Schulhoff N, Weinstock M, Pagala M, Ravindran K, Namba T, Nieto FJ, Stabler SP, Allen RH, Malinow MR. Relationship among homocysteine, Vitamin B-12 and cardiac disease in the elderly: association between vitamin B-12 deficiency and decreased left ventricular ejection fraction. J Nutr 1996; 126: S1249-53.
41. Kaysen GA, Rathore V, Shearer GC, Depner TA. Mechanisms of hypoalbuminemia in hemodialysis patients. Kidney Int 1995; 48: 510-6.
42. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 1-6.